Greenbaum Olbrantz LLP is investigating potential legal claims on behalf of cancer patients and their payors who have been harmed by potential unfair pricing of Revlimid, a medication that is essential to the treatment of multiple myeloma and certain blood cancers.
For many cancer patients, Revlimid is a mandatory drug with no available alternatives, and obtaining it is a matter of life or death. Revlimid obtained FDA approval in 2005, and it initially sold for $215 per capsule ($340 when adjusted for inflation today). As of early 2025, however, Revlimid has a list price of almost $900 per capsule, nearly three times the inflation-adjusted price.
ProPublica reports that the cost to produce one capsule of Revlimid has long been around 25 cents. Moreover, data provided by Revlimid’s manufacturer reveal that the aggregate cost of the drug’s research and development likely reflects merely one or two percent of the company’s total sales of the drug.
While there has been a substantial amount of litigation over the years alleging that Revlimid’s manufacturer has violated antitrust laws in its efforts to market Revlimid, our investigation is focusing on whether the manufacturer’s pricing strategies have potentially violated consumer protection statutes that prohibit unfair trade practices.
Have You Been Affected?
If you or your organization paid for Revlimid at any time since 2021, you may have legal rights and potential claims. If you believe that you may have been affected and would like to learn more, please complete the below form.
Please do not include any confidential information when submitting this form. No lawyer-client relationship is formed unless and until an engagement agreement is signed. By submitting this form, you consent to be contacted with more information.